AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12185153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo tablets) plus vitamin B-12 1 mg intramuscularly weekly.
Number of subjects: 138
Study 10094088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Learning to terminate eating when flavor pleasantness subsided; duration: 1 month
Number of subjects: 7
Study 8908233 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac IV before surgery
Number of subjects: 60
Study 8908233 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection after surgery
Number of subjects: 60
Study 2051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-protein-isolate, lactose-free formula (group SF)
Number of subjects: 85
Study 2051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat flour, pea flour, carrot flour, sucrose, and vegetable oil (group WP)
Number of subjects: 85
Study 2051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato flour, dried whole milk, carrot flour, sucrose, and oil (group PM)
Number of subjects: 85
Study 2051273 — intervention group
Group type: COMPARATOR
Intervention: All groups (SF, WP, PM)
Number of subjects: 85
Study 6851412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (200 to 900 mg)
Number of subjects: 5
Study 6851412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (89 or 134 gm absolute ethanol)
Number of subjects: 5
Study 6851412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6851412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital and Ethanol
Number of subjects: 5
Study 30837413 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 116
Study 30837413 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 116
Study 29177714 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy HIFU
Number of subjects: 20
Study 29177714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy HIFU
Number of subjects: 20
Study 29177714 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 26537365 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose beetroot juice (H-BT; 250 ml)
Number of subjects: 30
Study 26537365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose beetroot juice (L-BT; 125 ml)
Number of subjects: 30
Study 26537365 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA; 250 ml)
Number of subjects: 30
Study 24898304 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg, titrated to 50 mg)
Number of subjects: 101
Study 24898304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24898304 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 101
Study 24898304 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg, titrated to 4 mg)
Number of subjects: 101
Study 21853373 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism-specific medical home intervention
Number of subjects: 203
Study 21853373 — intervention group
Group type: COMPARATOR
Intervention: Standard primary medical care (Control)
Number of subjects: 203
Study 19442968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic user group receiving low-dose, monophasic OC pills for 24 months
Number of subjects: 311
Study 19442968 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous user group receiving low-dose, monophasic OC pills for 24 months
Number of subjects: 311
Study 19442968 — intervention group
Group type: COMPARATOR
Intervention: Nonuser group receiving no therapy
Number of subjects: 311
Study 19442968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic user group and Continuous user group
Number of subjects: 311
Study 17349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Geomagnetic field (48 microT)
Number of subjects: 0
Study 17349666 — intervention group
Group type: COMPARATOR
Intervention: No magnetic field
Number of subjects: 0
Study 15774699 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal 13C-labeled dipalmitoyl phosphatidylcholine administration
Number of subjects: 16
Study 15177063 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 mg daily)
Number of subjects: 100
Study 15177063 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone (500 mg daily)
Number of subjects: 100
Study 10457295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (10 mg/kg/day once daily)
Number of subjects: 42
Study 10457295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (10 mg/kg/day divided twice daily)
Number of subjects: 42
Study 10457295 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 42
Study 10457295 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (azithromycin, cefixime, no antibiotics)
Number of subjects: 42
Study 10457295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 42
Study 10457295 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 42
Study 7605179 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 times a week for 24 weeks, weights adapted to their force)
Number of subjects: 62
Study 1763537 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-40 mg/d
Number of subjects: 0
Study 1763537 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0
Study 1763537 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine with theophylline aminopropanol
Number of subjects: 0
Study 6762118 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.33 g/h of glucose during 6 hours
Number of subjects: 5
Study 6762118 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose during 6 hours
Number of subjects: 5
Study 6762118 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose with 20 mu insulin
Number of subjects: 5
Study 6762118 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose with 40 mu insulin
Number of subjects: 5
Study 6762118 — intervention group
Group type: COMPARATOR
Intervention: No glucose
Number of subjects: 5
Study 30470466 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 167
Study 30470466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no foot massage)
Number of subjects: 167
Study 28694687 — intervention group
Group type: EXPERIMENTAL
Intervention: VApal ophthalmic solution (500 IU/mL)
Number of subjects: 66
Study 28694687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 25750345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate i.v.
Number of subjects: 34
Study 25750345 — intervention group
Group type: COMPARATOR
Intervention: 4 mg zoledronic acid i.v.
Number of subjects: 34
Study 25287233 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 2 liters + ascorbic acid (Group A)
Number of subjects: 58
Study 25287233 — intervention group
Group type: COMPARATOR
Intervention: PEG 4 liters (Group B)
Number of subjects: 58
Study 21107544 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-dependent contractions loaded at 25% MVC
Number of subjects: 0
Study 21107544 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contractions (MVCs)
Number of subjects: 0
Study 21107544 — intervention group
Group type: COMPARATOR
Intervention: Isometric contractions
Number of subjects: 0
Study 19346816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter straight phase II trials with rigorous patient selection criteria
Number of subjects: 0
Study 19346816 — intervention group
Group type: COMPARATOR
Intervention: Randomized phase II trial and randomized discontinuation trial
Number of subjects: 0
Study 17326546 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 CBT session (week 1)
Number of subjects: 86
Study 17326546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 CBT sessions (weeks 1 and 5)
Number of subjects: 86
Study 17326546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 CBT sessions (biweekly)
Number of subjects: 86
Study 17326546 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 CBT sessions (weekly)
Number of subjects: 86
Study 17326546 — intervention group
Group type: COMPARATOR
Intervention: No-treatment waiting period (WL)
Number of subjects: 86
Study 15184276 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d) for 11 days
Number of subjects: 9
Study 15184276 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (190 mg/d) for 11 days
Number of subjects: 9
Study 15184276 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d)
Number of subjects: 9
Study 15184276 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (190 mg/d)
Number of subjects: 9
Study 12375800 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 0
Study 12375800 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/cisplatin therapy
Number of subjects: 0
Study 9666417 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Transplantation (PBT)
Number of subjects: 12
Study 9666417 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow Transplantation (BMT)
Number of subjects: 12
Study 9666417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PBT and BMT
Number of subjects: 12
Study 7866846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 cc of dye (Telebrix N, 30 g)
Number of subjects: 94
Study 7866846 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 cc of dye (Telebrix N, 30 g)
Number of subjects: 94
Study 7866846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 cc of dye (Telebrix N, 30 g)
Number of subjects: 94
Study 2503570 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of diflunisal given preoperatively
Number of subjects: 35
Study 2503570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of paracetamol (2 doses: preoperatively and 4 h postoperatively)
Number of subjects: 35
Study 2503570 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (diflunisal and paracetamol)
Number of subjects: 35
Study 346616 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate treatment
Number of subjects: 10
Study 346616 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 10
Study 31630089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 206
Study 31630089 — intervention group
Group type: COMPARATOR
Intervention: Group-based exercise and education
Number of subjects: 206
Study 30853151 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG plus ciclosporin (5 mg/kg per day for 5 days)
Number of subjects: 175
Study 30853151 — intervention group
Group type: COMPARATOR
Intervention: IVIG (conventional treatment)
Number of subjects: 175
Study 28025945 — intervention group
Group type: EXPERIMENTAL
Intervention: SpinalonTM (10-35 mg buspirone/100-350 mg levodopa/25-85 mg carbidopa)
Number of subjects: 45
Study 28025945 — intervention group
Group type: EXPERIMENTAL
Intervention: SpinalonTM
Number of subjects: 45
Study 28025945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25845225 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture combined with auricular acupressure
Number of subjects: 85
Study 25845225 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine Hydrochloride Capsules (5 mg, twice daily for 5 days, then for two weeks in subsequent cycles)
Number of subjects: 85
Study 25845225 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine Hydrochloride Capsules
Number of subjects: 85
Study 25845225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 23527716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 9 mg sodium hyaluronate plus saline solution
Number of subjects: 46
Study 23527716 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 46
Study 23112411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC)
Number of subjects: 74
Study 23112411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FLP)
Number of subjects: 74
Study 18462234 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% icodextrin solution
Number of subjects: 17
Study 18462234 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 17
Study 17342946 — intervention group
Group type: EXPERIMENTAL
Intervention: Step down procedure for comparing several treatments
Number of subjects: 0
Study 17342946 — intervention group
Group type: COMPARATOR
Intervention: Single step procedure proposed by Nakamura and Imada (2005)
Number of subjects: 0
Study 14982260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Number of subjects: 36
Study 14982260 — intervention group
Group type: COMPARATOR
Intervention: Saline dressings
Number of subjects: 36
Study 14982260 — intervention group
Group type: COMPARATOR
Intervention: Human skin construct
Number of subjects: 36
Study 11411626 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft lumbar support
Number of subjects: 20
Study 11411626 — intervention group
Group type: COMPARATOR
Intervention: No lumbar support
Number of subjects: 20
Study 10193285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 27 mg capsules, two doses before operation and three doses in the first 24 h after operation
Number of subjects: 60
Study 10193285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10193285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 27 mg capsules
Number of subjects: 60
Study 7822611 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision and individualized planned nursing care (Experimental Ward)
Number of subjects: 39
Study 7822611 — intervention group
Group type: COMPARATOR
Intervention: Control Ward (similar ward without intervention)
Number of subjects: 39
Study 3364636 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.25 mg/kg
Number of subjects: 40
Study 3364636 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 1.5 micrograms/kg
Number of subjects: 40
Study 30137415 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/GnRHa treatment
Number of subjects: 99
Study 30137415 — intervention group
Group type: COMPARATOR
Intervention: GH treatment only
Number of subjects: 99
Study 28801436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 370
Study 28801436 — intervention group
Group type: COMPARATOR
Intervention: Non-endoscopic sphincterotomy
Number of subjects: 370
Study 25226171 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroChamber Plus Flow-Vu (FV)
Number of subjects: 80
Study 25226171 — intervention group
Group type: COMPARATOR
Intervention: AeroChamber Plus (AC)
Number of subjects: 80
Study 24263042 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen supplementation
Number of subjects: 80
Study 24263042 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen supplementation (air group)
Number of subjects: 80
Study 21484769 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-tumor necrosis factor (anti-TNF) therapy
Number of subjects: 100
Study 21484769 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 21484769 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 100
Study 21484769 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF therapy
Number of subjects: 100
Study 21484769 — intervention group
Group type: EXPERIMENTAL
Intervention: fat-positive/inflammation-positive vertebral corners
Number of subjects: 100
Study 21484769 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline variations in inflammation
Number of subjects: 100
Study 21484769 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline variations in fat
Number of subjects: 100
Study 18498743 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 18498743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16831952 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ibandronate
Number of subjects: 0
Study 16831952 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate
Number of subjects: 0
Study 14528961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichannel classifiers (FLD and SVM)
Number of subjects: 0
Study 14528961 — intervention group
Group type: COMPARATOR
Intervention: Single-channel maximum likelihood (ML) classifier (T2W)
Number of subjects: 0
Study 11787477 — intervention group
Group type: EXPERIMENTAL
Intervention: β1-selective β-blocker
Number of subjects: 147
Study 9365346 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 30 needle insertions
Number of subjects: 114
Study 9365346 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 15 needle insertions
Number of subjects: 114
Study 9365346 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 13 needle insertions
Number of subjects: 114
Study 9365346 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 5 needle insertions
Number of subjects: 114
Study 9365346 — intervention group
Group type: COMPARATOR
Intervention: Original PM protocol
Number of subjects: 114
Study 1540440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual beam Doppler technique
Number of subjects: 18
Study 1540440 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 18
Study 2950392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 17
Study 2950392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal air at 0.1-0.2 bar)
Number of subjects: 17
Study 30457900 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (3 mg/kg)
Number of subjects: 9
Study 30457900 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-butorphanol (3 mg/kg for each drug)
Number of subjects: 9
Study 30457900 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (0.9% NaCl) solution (control treatment)
Number of subjects: 9
Study 27620902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BCM-BIS) for determining post-dialysis target weight (PDTW)
Number of subjects: 298
Study 27620902 — intervention group
Group type: COMPARATOR
Intervention: Clinical determination of post-dialysis target weight (PDTW)
Number of subjects: 298
Study 24680549 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30mg once daily
Number of subjects: 92
Study 24680549 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 2000IU twice daily
Number of subjects: 92
Study 22566016 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific simulated rehearsal (PsR)
Number of subjects: 20
Study 22566016 — intervention group
Group type: COMPARATOR
Intervention: Generic virtual reality (VR) warm-up
Number of subjects: 20
Study 22566016 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 20
Study 20976816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 27
Study 20976816 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 27
Study 18593093 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite
Number of subjects: 28
Study 18593093 — intervention group
Group type: COMPARATOR
Intervention: Hybrid resin composite
Number of subjects: 28
Study 16542794 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 42
Study 16542794 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 42
Study 12655966 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree users
Number of subjects: 66
Study 12655966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision tree)
Number of subjects: 66
Study 10722984 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program for first-degree relatives of breast cancer patients
Number of subjects: 90
Study 8992909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive lung ventilation (ALV)
Number of subjects: 20
Study 8992909 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandatory ventilation (CMV)
Number of subjects: 20
Study 8992909 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning effects
Number of subjects: 20
Study 15278578 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide premedication
Number of subjects: 211
Study 15278578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metoclopramide premedication)
Number of subjects: 211
Study 4085132 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular formal dietary advice (Group A)
Number of subjects: 21
Study 4085132 — intervention group
Group type: EXPERIMENTAL
Intervention: No dietary advice (Group B)
Number of subjects: 21
Study 4085132 — intervention group
Group type: COMPARATOR
Intervention: Thyrotoxic subjects (combined Group A and B)
Number of subjects: 21
Study 4085132 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (23 individuals)
Number of subjects: 21
Study 31351659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban (400-800 mg, taken 1 to 6 hours prior to sexual activity)
Number of subjects: 0
Study 31351659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27566125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood 25(OH)D
Number of subjects: 1040
Study 27502861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously every 2 weeks)
Number of subjects: 30000
Study 27502861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 30000
Study 27502861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study 25158896 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg methylprednisolone acetate mixed with 0.5 ml of 2% lidocaine) after 2 monthly saline placebo injections.
Number of subjects: 60
Study 25158896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose injection (0.5 ml of 20% DX mixed with 0.5 ml of 2% lidocaine) repeated monthly for 3 months.
Number of subjects: 60
Study 23372613 — intervention group
Group type: COMPARATOR
Intervention: Centers with fewer than 50 patients
Number of subjects: 8121